NRx Pharmaceuticals develops ketamine-based and other drugs for central nervous system disorders such as depression and PTSD. It last closed at $2.15 on Nov 20, down 15.69% on the day. The next earnings report for NRXP is expected around Mon, Feb 15, 2027. For the quarter ended Sep 2026, NRXP reported EPS of -$0.05 on revenue of $1.2M, with revenue up 378.9% from a year ago. Over its last 8 reports the stock moved an average of 5.8% the session after earnings.
AI Auto Pilots
Is NRXP in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold NRXP.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on NRXPStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
NRXP · as of the Nov 20 close · updated each morning
Downtrend
The stock is 12% below its 20 day and 27% below its 50 day average. It is 39% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 41). The nearest support is the swing low (Oct 30) at $2.11, and the nearest resistance the Pivot at $2.27.
Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityHigh, 11.4%/day
Key levels
$5.0552 week high+134.9%
$3.18100 day average+47.9%
$2.99200 day average+39.1%
$2.7250 day average+26.5%
$2.50Swing high (Nov 11)+16.3%
$2.4120 day average+12.1%
$2.41Pivot R1+12.1%
$2.27Pivot+5.6%
$2.15Last close
$2.11Swing low (Oct 30)−1.9%
$2.01Pivot S1−6.5%
$1.6252 week low−24.7%
Indicators
RSI (14)
41.44
Middle of its range
Neutral
MACD
-0.09
Above its signal line
Bullish
Stochastic
52.2
Middle of its range
Neutral
ADX (14)
29.5
Trending down
Williams %R
-88.6
Oversold below −80, overbought above −20
Oversold
CCI (20)
-66.3
Oversold below −100, overbought above 100
Neutral
Rate of change
−9.7%
Change over 10 sessions
Bearish
ATR (14)
$0.25
Typical daily range, 11.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Downtrend, nearing oversold
Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityNormal, 24.7%/day
Key levels
$5.0552 week high+134.9%
$3.18100 day average+47.9%
$2.99200 day average+39.1%
$2.7250 day average+26.5%
$2.50Swing high (Nov 11)+16.3%
$2.4120 day average+12.1%
$2.41Pivot R1+12.1%
$2.27Pivot+5.6%
$2.15Last close
$2.11Swing low (Oct 30)−1.9%
$2.01Pivot S1−6.5%
$1.6252 week low−24.7%
Indicators
RSI (14)
34.39
Weak, oversold below 30
Neutral
MACD
-0.25
Below its signal line
Bearish
Stochastic
8.1
Near the bottom of its range
Oversold
ADX (14)
23.1
Weak trend
Williams %R
-94.0
Oversold below −80, overbought above −20
Oversold
CCI (20)
-105.8
Oversold below −100, overbought above 100
Oversold
Rate of change
−36.8%
Change over 10 sessions
Bearish
ATR (14)
$0.53
Typical daily range, 24.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for NRXP
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how NRXP did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow NRXP usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for NRXPHow many large options trades hit NRXP, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in NRXP in the last 90 days.
From SEC Form 4 filings by NRXP's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NRXP is in one of them and how their past NRXP trades turned out.
NRx Pharmaceuticals is a drug developer based in Wilmington, Delaware, focused on treatments for central nervous system disorders such as depression, post traumatic stress disorder, chronic pain and schizophrenia. Its lead product candidates are ketamine formulations, including a generic version called KETAFREE, and NRX-101, a combination of D-cycloserine and lurasidone, all still awaiting approval from the U.S. Food and Drug Administration. Through its majority owned subsidiary HOPE Therapeutics, the company also runs clinics in Florida that offer interventional psychiatry care to patients with treatment resistant depression and PTSD.